Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
about
Invasion and metastasis in pancreatic cancerPathways for aberrant angiogenesis in pancreatic cancerInterleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expressionIdentification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesisIdentification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC)Current and future intraoperative imaging strategies to increase radical resection rates in pancreatic cancer surgery.Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia.Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer.Down-regulation of Bax-interacting factor 1 in human pancreatic ductal adenocarcinomaMUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.Analysis of the human pancreatic stellate cell secreted proteome.Pancreas recovery following cerulein-induced pancreatitis is impaired in plasminogen-deficient mice.Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway.Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitisRole of proteases in pancreatic carcinoma.Synthesis and biological characterization of protease-activated prodrugs of doxazolidineMolecular Imaging with MRI: Potential Application in Pancreatic Cancer.Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies.The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cellsPlasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer.Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single targetAmplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group.Receptor-targeted nanoparticles for in vivo imaging of breast cancer.Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases.uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.A pilot study of urokinase-type plasminogen activator (uPA) overexpression in the brush cytology of patients with malignant pancreatic or biliary strictures.Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
P2860
Q24800065-FF03790E-E622-4783-82FE-2BF3E4050B30Q24800215-41CEA803-572B-4734-BCCC-A05D294D9A0CQ25257709-A67F3AE9-5AAE-4439-8945-753573680FF6Q27681464-C39BE47B-3891-46D4-9082-2B70FD34C7DBQ28397726-AD1B708A-C57C-419C-BCB4-C14728FEF51EQ30354565-60208B8D-D717-4A40-A7B1-F904EB6F43FDQ30539738-E73B69AC-8BD2-4A1F-A3DA-8025107C7553Q31038443-9E1A9E94-5F61-4252-87D8-0FF6384FD765Q33676610-9B0DA90F-2824-4620-9AE5-E55E472E2C0AQ33703133-6E080F6E-ED0F-424A-8F4A-3ED5F4367F0BQ33741828-65A1C884-F3DF-410A-8950-5D290CE9E09CQ33856467-B6EDD8CF-30DC-48FD-AC25-AC243CDA7AA5Q34009539-15121E89-B638-4140-874C-CD9F52AAAE73Q34075406-88F86C64-C764-4D57-B0F8-A66434C68D9CQ34075984-36D5E876-5FF1-4F8B-A32E-BA98F5AACAE7Q34095789-2094E2B3-DE0E-472E-A226-F7E2A51B43ABQ34714192-4B274D22-8D47-436B-915A-ADBD4BDBB29CQ34737810-FA0C74E1-8EB7-4F8D-BB9F-4481474224B8Q34909004-88854FF4-3C05-4417-8931-EA47E2B367E5Q35130515-93136E04-D1B0-4E56-8F30-F3DACFAFB62DQ35574587-E6431B68-8350-44F4-98FC-DDD80EED2BF2Q35596926-E6854926-448E-4096-B610-BD699F66E63DQ35672193-62479676-DE06-4B2C-9C2C-83536F604449Q35787823-03557FB0-B3B2-460D-9DF3-34EF554CA485Q36038469-275F5435-1BE1-4254-AF6A-D40CB71AC111Q36206886-8FEB551C-3611-46DA-99BE-6CEC5D1FD321Q36249508-9F2CE23A-36E2-455B-8DA9-5EA4DB09F035Q36431096-8E324E86-0473-44ED-9986-C5734EB51761Q36490167-2BA7105A-31CD-423E-9AC6-D864D9C464EEQ36507581-497B7967-88C9-4F2C-82B4-BCC705C0E1ACQ36615378-935E3907-B04A-424A-94EC-DDBEC62F1237Q36721737-E3B30741-22E0-4D3F-9039-EFF4218E77B6Q36997621-05911430-D6DF-4BE3-B36A-9C9D9ECE63DDQ37197386-75B48760-57BF-4224-ADEA-C3DD24DD9F0EQ37307237-DA127E1C-8951-4ABF-A9C0-D785C56E3C4AQ37389699-3027ECC8-A046-44B2-A01E-939EF1E731B5Q37419308-8828CC4B-DAC6-4A1C-A14B-7825AE8BF1A0Q37435242-166C8816-EDED-44FF-8518-62C246022F32Q37452991-267A58B6-02C2-480D-B9D9-8D615584AEE2Q37801943-E61AD401-5185-406A-B4DE-E6B329CEB4EE
P2860
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Enhanced expression of urokina ...... eptor in pancreatic carcinoma.
@ast
Enhanced expression of urokina ...... eptor in pancreatic carcinoma.
@en
type
label
Enhanced expression of urokina ...... eptor in pancreatic carcinoma.
@ast
Enhanced expression of urokina ...... eptor in pancreatic carcinoma.
@en
prefLabel
Enhanced expression of urokina ...... eptor in pancreatic carcinoma.
@ast
Enhanced expression of urokina ...... eptor in pancreatic carcinoma.
@en
P2093
P2860
P356
P1476
Enhanced expression of urokina ...... eptor in pancreatic carcinoma.
@en
P2093
A Zimmermann
J Deflorin
M A Bründler
P2860
P2888
P304
P356
10.1038/BJC.1997.63
P407
P577
1997-01-01T00:00:00Z